<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03835273</url>
  </required_header>
  <id_info>
    <org_study_id>19SM5007</org_study_id>
    <nct_id>NCT03835273</nct_id>
  </id_info>
  <brief_title>Oesophagectomy and Chest Wall and Respiratory Function</brief_title>
  <official_title>Changes in Respiratory Function and Chest Wall Movement Following Oesophagectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open surgery for esophageal cancer commonly involves large incisions in the chest, associated&#xD;
      with a high rate of pulmonary complications (30-50%). Minimally invasive approach through&#xD;
      keyhole surgery has been shown to reduce pulmonary infections by 20%. Enhanced recovery&#xD;
      programmes are evidence-based protocols, developed to achieve early recovery after surgery&#xD;
      with early mobilisation and chest physiotherapy and have been shown to reduce pulmonary&#xD;
      complication rates as well. The investigators intend to objectively measure chest wall&#xD;
      movement using 3D motion capture system as well as a wearable measurement system to monitor&#xD;
      chest wall movement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population consists of 50 healthy volunteers who have not received upper&#xD;
      gastrointestinal surgery and 100 patients treated with surgery more than one year ago (50&#xD;
      open and 50 minimally invasive). Chest wall movement will be measured using a 3D optical&#xD;
      motion system and the investigators will establish if inertial measurement units placed&#xD;
      strategically on the chest wall are able to quantify chest expansion and lung capacity. Data&#xD;
      will be acquired during different breathing patterns and during use of an incentive&#xD;
      spirometry. Pulmonary function tests will be undertaken in all patients and the investigators&#xD;
      will also collect clinical data concerning health-related quality of life and other&#xD;
      concomitant medical conditions. The target outcome of this study is to determine whether the&#xD;
      3D motion capture and wearable systems are reliable in the measurement of chest wall movement&#xD;
      after surgical removal of esophagus and the validity and patient acceptability of wearable&#xD;
      system, as well as the ability of distinguishing open and minimally invasive surgical&#xD;
      approach. A tailored physiotherapy may be developed following this study in order to improve&#xD;
      chest wall movement and objectively measure this using the wearable system. This can then be&#xD;
      implemented in a clinical trial to provide the evidence base to for patient-tailored&#xD;
      physiotherapy following major cancer surgery and to optimise the respiratory function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chest wall movement</measure>
    <time_frame>Each participant will undergone one assessment during the study. The whole session, all procedures included, will last approximately 60 minutes.</time_frame>
    <description>Evaluation of changes in chest wall movement in patients who have undergone oesophagectomy more than a year ago (open or minimally invasive approach) and in healthy control participants. Reflective markers will be placed on the chest wall of the participant and chest wall movement will be detected by a 3D motion capture system using these markers. In addition, inertia measurement units will be applied next to the markers. Chest wall movement will be assessed during normal breathing, take and hold a deep breath and whilst performing incentive spirometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung function</measure>
    <time_frame>Each participant will undergone one assessment during the study. The whole session, all procedures included, will last approximately 60 minutes.</time_frame>
    <description>Patients will be asked to perform incentive spirometry which is a non-invasive assessment of the lung function. The forced expiratory volume in 1 second (FEV1) and the forced vital capacity (FVC) will be recorded for all participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life in cancer patients</measure>
    <time_frame>Each participant will undergone one assessment during the study. The whole session, all procedures included, will last approximately 60 minutes.</time_frame>
    <description>All participants will be asked to fill in a validated questionnaire, the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) for assessment of their current quality of life. The QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Items 1 to 28 have a four-point scale response, namely 'Not at all' (point 1), 'A little', 'Quite a bit' and 'Very much' (point 4). The last 2 items have a seven-point scale for assessment of the overall health and overall quality of life, being 'Very poor' (point 1) to 'Excellent (points 7). Higher scores in the function and global quality of life scales represent better levels outcome, whilst higher scores in symptom scales represent presence of more symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life in patients with tumours of the oesophagus, oesophago-gastric junction or stomach</measure>
    <time_frame>Each participant will undergone one assessment during the study. The whole session, all procedures included, will last approximately 60 minutes.</time_frame>
    <description>All participants will be asked to fill in a validated questionnaire, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Oesophago-Gastric Module 25 (EORTC QLQ-OG25) for assessment of their current quality of life. The QLQ-OG25 has six symptom scales (dysphagia, eating restrictions, reflux, odynophagia, pain and discomfort, and a scale assessing anxiety) and 10 single items relevant to patients undergoing palliative or potentially curative treatments and follow-up for upper gastrointestinal cancer. All items have four-point scale, namely 'Not at all' (point 1), 'A little', 'Quite a bit' and 'Very much' (point 4). Higher scores in symptom scales represent presence of more symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Usability and acceptability of the measuring device</measure>
    <time_frame>Each participant will undergone one assessment during the study. The whole session, all procedures included, will last approximately 60 minutes.</time_frame>
    <description>All participants will be asked to fill in a satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system. This questionnaire includes a total of 10 items assessing the usability and acceptability of the 3D motion capture system. Each item has a five-point Likert scale response, with 'Strongly disagree' (point 1), 'Disagree', 'Neutral', 'Agree' and 'Strongly agree' (point 5). Higher scores correspond with better outcome.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Esophagectomy</condition>
  <condition>Respiratory Function Loss</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Fifty control participants who have not received upper gastrointestinal surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimally invasive surgery</arm_group_label>
    <description>Fifty patients who have undergone minimally invasive removal of oesophagus more than one year ago.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open surgery</arm_group_label>
    <description>Fifty patients who have undergone open removal of oesophagus more than one year ago.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3D motion capture system</intervention_name>
    <description>Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Minimally invasive surgery</arm_group_label>
    <arm_group_label>Open surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Incentive spirometry</intervention_name>
    <description>Incentive spirometry is a non-invasive device for assessment of pulmonary function.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Minimally invasive surgery</arm_group_label>
    <arm_group_label>Open surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Two validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and one non-validated satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system [7,8]</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Minimally invasive surgery</arm_group_label>
    <arm_group_label>Open surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Three cohorts will be studied, equal in size. A total of 150 patients will be included in&#xD;
        this study. One hundred patients who have undergone oesophagectomy for oesophageal cancer&#xD;
        more than a year ago, 50 patients who have undergone open surgery and 50 who have undergone&#xD;
        a minimally invasive approach. In addition, 50 healthy volunteers will be included as a&#xD;
        control group with no underlying respiratory disease and no previous history of upper&#xD;
        gastrointestinal surgery.&#xD;
&#xD;
        Patients who have undergone oesophagectomy will be identified from existing databases by&#xD;
        the direct care team of the patient. Healthy volunteers will be recruited from Imperial&#xD;
        College through paper adverts.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Exposure group:&#xD;
&#xD;
               1. Patients treated more than a year ago with oesophagectomy for oesophageal cancer,&#xD;
                  either by an open approach or minimally invasive surgery.&#xD;
&#xD;
               2. Patients able to understand and retain the information provided, thereby being&#xD;
                  able to give informed consent for inclusion in this study.&#xD;
&#xD;
          -  Control group:&#xD;
&#xD;
               1. Healthy volunteers with no underlying respiratory disease and no history of upper&#xD;
                  gastrointestinal surgery.&#xD;
&#xD;
               2. Individuals able to understand and retain the information provided, thereby being&#xD;
                  able to give informed consent for inclusion in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any participant who lacks capacity or is unable to provide informed consent.&#xD;
&#xD;
          -  Any participant younger than 18 or older than 90 years of age.&#xD;
&#xD;
          -  Any patient with evidence of cancer recurrence or on-going postoperative complication&#xD;
             at more than one year following surgery for oesophageal cancer.&#xD;
&#xD;
          -  Any pregnant participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheraz R Markar, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheraz R Markar, Dr</last_name>
    <phone>+44203312 2125</phone>
    <email>s.markar@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karina Tukanova</last_name>
    <phone>+447751844678</phone>
    <email>karina.tukanova17@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Tukanova, MD</last_name>
      <phone>+447751844678</phone>
      <email>karina.tukanova17@imperial.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Shirinzadeh A, Talebi Y. Pulmonary Complications due to Esophagectomy. J Cardiovasc Thorac Res. 2011;3(3):93-6. doi: 10.5681/jcvtr.2011.020. Epub 2011 Aug 20.</citation>
    <PMID>24250962</PMID>
  </reference>
  <reference>
    <citation>Nagawa H, Kobori O, Muto T. Prediction of pulmonary complications after transthoracic oesophagectomy. Br J Surg. 1994 Jun;81(6):860-2. doi: 10.1002/bjs.1800810622.</citation>
    <PMID>8044603</PMID>
  </reference>
  <reference>
    <citation>Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, Gisbertz SS, Klinkenbijl JH, Hollmann MW, de Lange ES, Bonjer HJ, van der Peet DL, Cuesta MA. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012 May 19;379(9829):1887-92. doi: 10.1016/S0140-6736(12)60516-9. Epub 2012 May 1.</citation>
    <PMID>22552194</PMID>
  </reference>
  <reference>
    <citation>Kubo N, Ohira M, Yamashita Y, Sakurai K, Toyokawa T, Tanaka H, Muguruma K, Shibutani M, Yamazoe S, Kimura K, Nagahara H, Amano R, Ohtani H, Yashiro M, Maeda K, Hirakawa K. The impact of combined thoracoscopic and laparoscopic surgery on pulmonary complications after radical esophagectomy in patients with resectable esophageal cancer. Anticancer Res. 2014 May;34(5):2399-404.</citation>
    <PMID>24778050</PMID>
  </reference>
  <reference>
    <citation>Schmidt HM, El Lakis MA, Markar SR, Hubka M, Low DE. Accelerated Recovery Within Standardized Recovery Pathways After Esophagectomy: A Prospective Cohort Study Assessing the Effects of Early Discharge on Outcomes, Readmissions, Patient Satisfaction, and Costs. Ann Thorac Surg. 2016 Sep;102(3):931-939. doi: 10.1016/j.athoracsur.2016.04.005. Epub 2016 Jun 7.</citation>
    <PMID>27283109</PMID>
  </reference>
  <reference>
    <citation>Li C, Ferri LE, Mulder DS, Ncuti A, Neville A, Lee L, Kaneva P, Watson D, Vassiliou M, Carli F, Feldman LS. An enhanced recovery pathway decreases duration of stay after esophagectomy. Surgery. 2012 Oct;152(4):606-14; discussion 614-6. doi: 10.1016/j.surg.2012.07.021. Epub 2012 Sep 1.</citation>
    <PMID>22943844</PMID>
  </reference>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.</citation>
    <PMID>8433390</PMID>
  </reference>
  <reference>
    <citation>Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, Hammerlid E, Bottomley A, Van Cutsem E, Blazeby JM; European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life Groups. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer. 2007 Sep;43(14):2066-73. doi: 10.1016/j.ejca.2007.07.005. Epub 2007 Aug 15.</citation>
    <PMID>17702567</PMID>
  </reference>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2019</study_first_posted>
  <last_update_submitted>March 30, 2022</last_update_submitted>
  <last_update_submitted_qc>March 30, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophagectomy</keyword>
  <keyword>Motion capture</keyword>
  <keyword>Respiratory</keyword>
  <keyword>Oesophageal cancer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03835273
org study id: 19SM5007
nct id: NCT03835273
lead sponsor: 
is fda regulated drug: No
is fda regulated device: No
Open surgery for esophageal cancer commonly involves large incisions in the chest, associated
      with a high rate of pulmonary complications (30-50%). Minimally invasive approach through
      keyhole surgery has been shown to reduce pulmonary infections by 20%. Enhanced recovery
      programmes are evidence-based protocols, developed to achieve early recovery after surgery
      with early mobilisation and chest physiotherapy and have been shown to reduce pulmonary
      complication rates as well. The investigators intend to objectively measure chest wall
      movement using 3D motion capture system as well as a wearable measurement system to monitor
      chest wall movement.
The study population consists of 50 healthy volunteers who have not received upper
      gastrointestinal surgery and 100 patients treated with surgery more than one year ago (50
      open and 50 minimally invasive). Chest wall movement will be measured using a 3D optical
      motion system and the investigators will establish if inertial measurement units placed
      strategically on the chest wall are able to quantify chest expansion and lung capacity. Data
      will be acquired during different breathing patterns and during use of an incentive
      spirometry. Pulmonary function tests will be undertaken in all patients and the investigators
      will also collect clinical data concerning health-related quality of life and other
      concomitant medical conditions. The target outcome of this study is to determine whether the
      3D motion capture and wearable systems are reliable in the measurement of chest wall movement
      after surgical removal of esophagus and the validity and patient acceptability of wearable
      system, as well as the ability of distinguishing open and minimally invasive surgical
      approach. A tailored physiotherapy may be developed following this study in order to improve
      chest wall movement and objectively measure this using the wearable system. This can then be
      implemented in a clinical trial to provide the evidence base to for patient-tailored
      physiotherapy following major cancer surgery and to optimise the respiratory function.
observational model: Cohort
time perspective: Prospective
measure: Chest wall movement
time frame: Each participant will undergone one assessment during the study. The whole session, all procedures included, will last approximately 60 minutes.
description: Evaluation of changes in chest wall movement in patients who have undergone oesophagectomy more than a year ago (open or minimally invasive approach) and in healthy control participants. Reflective markers will be placed on the chest wall of the participant and chest wall movement will be detected by a 3D motion capture system using these markers. In addition, inertia measurement units will be applied next to the markers. Chest wall movement will be assessed during normal breathing, take and hold a deep breath and whilst performing incentive spirometry.
measure: Lung function
time frame: Each participant will undergone one assessment during the study. The whole session, all procedures included, will last approximately 60 minutes.
description: Patients will be asked to perform incentive spirometry which is a non-invasive assessment of the lung function. The forced expiratory volume in 1 second (FEV1) and the forced vital capacity (FVC) will be recorded for all participants.
measure: Health-related Quality of Life in cancer patients
time frame: Each participant will undergone one assessment during the study. The whole session, all procedures included, will last approximately 60 minutes.
description: All participants will be asked to fill in a validated questionnaire, the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) for assessment of their current quality of life. The QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Items 1 to 28 have a four-point scale response, namely 'Not at all' (point 1), 'A little', 'Quite a bit' and 'Very much' (point 4). The last 2 items have a seven-point scale for assessment of the overall health and overall quality of life, being 'Very poor' (point 1) to 'Excellent (points 7). Higher scores in the function and global quality of life scales represent better levels outcome, whilst higher scores in symptom scales represent presence of more symptoms.
measure: Health-related Quality of Life in patients with tumours of the oesophagus, oesophago-gastric junction or stomach
time frame: Each participant will undergone one assessment during the study. The whole session, all procedures included, will last approximately 60 minutes.
description: All participants will be asked to fill in a validated questionnaire, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Oesophago-Gastric Module 25 (EORTC QLQ-OG25) for assessment of their current quality of life. The QLQ-OG25 has six symptom scales (dysphagia, eating restrictions, reflux, odynophagia, pain and discomfort, and a scale assessing anxiety) and 10 single items relevant to patients undergoing palliative or potentially curative treatments and follow-up for upper gastrointestinal cancer. All items have four-point scale, namely 'Not at all' (point 1), 'A little', 'Quite a bit' and 'Very much' (point 4). Higher scores in symptom scales represent presence of more symptoms.
measure: Usability and acceptability of the measuring device
time frame: Each participant will undergone one assessment during the study. The whole session, all procedures included, will last approximately 60 minutes.
description: All participants will be asked to fill in a satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system. This questionnaire includes a total of 10 items assessing the usability and acceptability of the 3D motion capture system. Each item has a five-point Likert scale response, with 'Strongly disagree' (point 1), 'Disagree', 'Neutral', 'Agree' and 'Strongly agree' (point 5). Higher scores correspond with better outcome.
arm group label: Control group
description: Fifty control participants who have not received upper gastrointestinal surgery.
arm group label: Minimally invasive surgery
description: Fifty patients who have undergone minimally invasive removal of oesophagus more than one year ago.
arm group label: Open surgery
description: Fifty patients who have undergone open removal of oesophagus more than one year ago.
intervention type: Other
intervention name: 3D motion capture system
description: Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
arm group label: Control group
arm group label: Minimally invasive surgery
arm group label: Open surgery
intervention type: Other
intervention name: Incentive spirometry
description: Incentive spirometry is a non-invasive device for assessment of pulmonary function.
arm group label: Control group
arm group label: Minimally invasive surgery
arm group label: Open surgery
intervention type: Other
intervention name: Questionnaires
description: Two validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and one non-validated satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system [7,8]
arm group label: Control group
arm group label: Minimally invasive surgery
arm group label: Open surgery
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: 90 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Sheraz R Markar, Dr
role: Principal Investigator
affiliation: Imperial College London
last name: Sheraz R Markar, Dr
phone: +44203312 2125
email: s.markar@imperial.ac.uk
last name: Karina Tukanova
phone: +447751844678
email: karina.tukanova17@imperial.ac.uk
facility: 
status: Recruiting
contact: 
country: United Kingdom
citation: Shirinzadeh A, Talebi Y. Pulmonary Complications due to Esophagectomy. J Cardiovasc Thorac Res. 2011;3(3):93-6. doi: 10.5681/jcvtr.2011.020. Epub 2011 Aug 20.
PMID: 24250962
citation: Nagawa H, Kobori O, Muto T. Prediction of pulmonary complications after transthoracic oesophagectomy. Br J Surg. 1994 Jun;81(6):860-2. doi: 10.1002/bjs.1800810622.
PMID: 8044603
citation: Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, Gisbertz SS, Klinkenbijl JH, Hollmann MW, de Lange ES, Bonjer HJ, van der Peet DL, Cuesta MA. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012 May 19;379(9829):1887-92. doi: 10.1016/S0140-6736(12)60516-9. Epub 2012 May 1.
PMID: 22552194
citation: Kubo N, Ohira M, Yamashita Y, Sakurai K, Toyokawa T, Tanaka H, Muguruma K, Shibutani M, Yamazoe S, Kimura K, Nagahara H, Amano R, Ohtani H, Yashiro M, Maeda K, Hirakawa K. The impact of combined thoracoscopic and laparoscopic surgery on pulmonary complications after radical esophagectomy in patients with resectable esophageal cancer. Anticancer Res. 2014 May;34(5):2399-404.
PMID: 24778050
citation: Schmidt HM, El Lakis MA, Markar SR, Hubka M, Low DE. Accelerated Recovery Within Standardized Recovery Pathways After Esophagectomy: A Prospective Cohort Study Assessing the Effects of Early Discharge on Outcomes, Readmissions, Patient Satisfaction, and Costs. Ann Thorac Surg. 2016 Sep;102(3):931-939. doi: 10.1016/j.athoracsur.2016.04.005. Epub 2016 Jun 7.
PMID: 27283109
citation: Li C, Ferri LE, Mulder DS, Ncuti A, Neville A, Lee L, Kaneva P, Watson D, Vassiliou M, Carli F, Feldman LS. An enhanced recovery pathway decreases duration of stay after esophagectomy. Surgery. 2012 Oct;152(4):606-14; discussion 614-6. doi: 10.1016/j.surg.2012.07.021. Epub 2012 Sep 1.
PMID: 22943844
citation: Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
PMID: 8433390
citation: Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, Hammerlid E, Bottomley A, Van Cutsem E, Blazeby JM; European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life Groups. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer. 2007 Sep;43(14):2066-73. doi: 10.1016/j.ejca.2007.07.005. Epub 2007 Aug 15.
PMID: 17702567
responsible party type: Sponsor
sharing ipd: No